CASE REPORT

Genetic heterogeneity in a patient with Muir-Torre syndrome

Ruonan Zhang, MD, PhD,a Chinmoy Bhate, MD,b, and Donghong Cai, MD, PhDc
Newark and East Orange, New Jersey

Key words: genetic heterogeneity; MMR genes; Muir-Torre syndrome; sebaceous adenoma.

INTRODUCTION

Muir-Torre syndrome is an autosomal-dominant disorder caused by germline mutations in 1 of the 4 key DNA mismatch repair (MMR) genes, MSH2, MSH6, PMS2, and MLH1. Patients with Muir-Torre syndrome present with skin lesions, which play an important role in early detection of the disease and are considered cutaneous markers. The diagnostic criteria for Muir-Torre syndrome are at least 1 skin neoplasm with sebaceous differentiation, at least 1 visceral malignancy, and germline mutation of the MMR genes.1,2 Sebaceous adenoma is rare and is considered the most significant cutaneous marker for Muir-Torre syndrome.3 Abbas and Mahalingam4 suggested that when a young patient presents with a sebaceous neoplasm outside the head and neck area, immunohistochemical analysis of the MMR genes should be conducted for Muir-Torre syndrome screening. If loss of any MMR proteins is identified, microsatellite instability study or germline analysis is warranted for further diagnosis. In addition, presence of multiple keratoacanthomas should also prompt immunostaining studies for screening.3 In Muir-Torre syndrome, the keratoacanthoma usually presents with sebaceous differentiation.3

For a specific patient, loss of MMR proteins in the skin lesions and in the visceral tumors should be in concordance because of the presence of germline mutation. However, here we examined a visceral tumor and all 16 skin lesions from a patient with Muir-Torre syndrome and found genetic heterogeneity among several samples. All 13 sebaceous adenomas and the visceral tumor showed the same expression pattern of the MMR genes in line with the germline mutation, whereas other skin lesions such as keratoacanthoma and squamous cell carcinoma (SCC) showed aberrant expression patterns. To our knowledge, this is the first study reporting the phenomenon of genetic heterogeneity in a Muir-Torre syndrome patient.

CASE REPORT

A 63-year-old man presented with sebaceous adenomas, keratoacanthomas, SCCs, and transverse colon adenocarcinoma he had had for years. Germline mutation analysis by using peripheral blood detected the familial MSH2 variant c.942 + 3A>T, also known as IVS5 + 3A>T, in heterozygous state (LabCorp, Research Triangle, NC). This variant of MSH2 has been associated with an increased risk for Lynch syndrome.5 Together with the sebaceous neoplasm and colonic adenocarcinoma, this patient met the diagnostic criteria for Muir-Torre syndrome.

A review of the patient’s pathology tallied a total of 17 specimens, including 1 colonic adenocarcinoma and 16 skin biopsies. Among the skin lesions, there were 13 sebaceous adenomas, 2 keratoacanthomas, and 1 SCC. Fig 1 shows 3 representative gross skin lesions, all of which presented as red papules, with 1 identified on the nose (Fig 1, A) and the other 2 on the back (Fig 1, B and C). All 3 lesions

Abbreviations used:

MMR: mismatch repair
SCC: squamous cell carcinoma

From the Department of Pathologya and Department of Dermatology,b Rutgers New Jersey Medical School, Newark; and Pathology and Lab Medicine Services, VA New Jersey Medical Center, East Orange.c

Funding sources: None.

Conflicts of interest: None disclosed.

Correspondence to: Ruonan Zhang, MD, PhD, Department of Pathology, Immunology and Laboratory Medicine, Rutgers New Jersey Medical School, 150 Bergen St, Newark, NJ 07103. E-mail: rz250@njms.rutgers.edu.
proved to be sebaceous adenoma according to histopathology. We performed immunostaining for MSH2, MSH6, PMS2, and MLH1 on all 16 skin lesions and the colonic adenocarcinoma to examine their expression status. All 13 sebaceous adenomas, the colonic adenocarcinoma, and 1 of the 2 keratoacanthomas showed loss of MSH2 and MSH6 expression but retained PMS2 and MLH1 expression. This is consistent with the patient’s germline mutation in MSH2 (the absence of MSH2 leads to loss of MSH6 because these 2 proteins form heterodimers and play an important role in DNA damage repair as a function unit6). The immunostain for the MMR proteins on a representative sebaceous adenoma is shown in Fig 2. In contrast, the immunostain for the MMR proteins on the SCC showed loss of PMS2 and retained MSH2, MSH6, and MLH1 (Fig 3). In addition, the other keratoacanthoma shows retention of all 4 MMR genes. The SCC and the 2 keratoacanthomas had no sebaceous differentiation. The 2 keratoacanthomas and their different immunostaining pattern of MSH2 and MSH6 are shown in Fig 4. The immunostaining results on all the skin lesions are summarized in Table 1.

**DISCUSSION**

Here we report a case of a 63-year-old man with Muir-Torre syndrome presenting with colonic adenocarcinoma and multiple skin lesions, including 13 sebaceous adenomas, 2 keratoacanthomas, and 1 SCC. All of the sebaceous adenomas and the colonic adenocarcinoma showed no deviation of MMR expression pattern from the germline mutation, but the other skin lesions, including the SCC and keratoacanthomas, showed heterogeneity with either no loss of MMR proteins or loss of a different MMR protein. Our study suggests that in Muir-Torre syndrome patients, the MMR genetic change is faithful in sebaceous adenomas but less so in squamous neoplasms.

Keratoacanthomas can occur in up to 20% of Muir-Torre syndrome patients with or without a concurrent sebaceous neoplasm. Simultaneous multiple keratoacanthomas or keratoacanthoma with sebaceous differentiation can be highly suggestive of Muir-Torre syndrome. We identified 2 keratoacanthomas on our patient and neither of them showed sebaceous differentiation. However, one keratoacanthoma lost MSH2 and MSH6 proteins (in

---

**Table 1**

| Skin Lesion Type | MMR Expression Pattern |
|-----------------|------------------------|
| Sebaceous Adenomas | All 2 proteins retained |
| Colonic Adenocarcinoma | All proteins retained |
| Keratoacanthoma 1 | MSH2 and MSH6 lost, PMS2 and MLH1 retained |
| Keratoacanthoma 2 | All proteins retained |
| SCC              | MSH2 and MSH6 lost, PMS2 and MLH1 retained |

---

**Fig 1.** Representative gross skin lesions. A red papule identified on the nose (A) and 2 red papules on the back (B, C). All the lesions were proven to be sebaceous adenoma according to histopathology.
alignment with the germline mutation), whereas the other had no loss of MMR expression. This finding suggests genetic heterogeneity behind keratoacanthoma development in Muir-Torre syndrome patients.

To date, the relationship between SCC and Muir-Torre syndrome has not been well clarified. A few studies reported an association of SCC and Muir-Torre syndrome,^7^-^9^ in which the expression pattern of MMR genes in the SCC was the same as the germline mutation. However, the SCC in our case showed loss of PMS2, whereas germline mutation was on MSH2. It is uncertain whether the loss of PMS2 in the SCC is related to germline mutation of MSH2 or is just a sporadic event.

In conclusion, by studying the pathology of the specimens from a patient with Muir-Torre syndrome, we confirmed that sebaceous adenomas are faithful
Fig 3. Hematoxylin-eosin stain of the squamous cell carcinoma and immunostains of the MMR genes. A, Squamous cell carcinoma, moderately differentiated. Immunostain with MSH2 (B), MSH6 (C), and MLH1 (D) showing that the proteins are retained in squamous cell carcinoma. E, Immunostain with PMS2 showing that the protein is lost in squamous cell carcinoma. (A, Hematoxylin-eosin stain; original magnification: ×200.)
with germline MMR mutation and therefore are valuable material for early screening of Muir-Torre syndrome. In contrast, keratoacanthomas and SCCs show different expression pattern of the MMR genes and exhibit a phenomenon of genetic heterogeneity.

REFERENCES

1. Muir EG, Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg. 1967;54(3):191-195.
2. Torre D. Multiple sebaceous tumors. Arch Dermatol. 1968;98(5):549-551.
3. John AM, Schwartz RA. Muir-Torre syndrome (MTS): an update and approach to diagnosis and management. J Am Acad Dermatol. 2016;74:558-566.

**Table I.** Summary of the mismatch repair gene expression patterns in the colorectal adenocarcinoma and all the skin lesions in the Muir-Torre syndrome patient

| Tumors                        | MMR genes |      |      |      |      |
|-------------------------------|-----------|------|------|------|------|
| Colorectal adenocarcinoma     |           |      |      |      |      |
| All 13 sebaceous adenomas     |           |      |      |      |      |
| Squamous cell carcinoma       | +         |      |      |      |      |
| Keratoacanthoma 1             |           |      |      |      |      |
| Keratoacanthoma 2             | +         | +    | +    |      |      |

MMR, Mismatch repair.
4. Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J Cutan Pathol. 2009;36:613-619.

5. Martinez-Bouzas C, Beristain E, Ojembarrena E, et al. A study on MSH2 and MLH1 mutations in hereditary nonpolyposis colorectal cancer families from the Basque country, describing four new germline mutations. Fam Cancer. 2009;8(4):533-539.

6. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18(1):85-98.

7. Sorscher S. A case of squamous cell carcinoma of the skin due to the molecularly confirmed Lynch syndrome. Hered Cancer Clin Pract. 2015;13(1):12.

8. Kientz C, Joly MO, Faivre L, et al. A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma. Hered Cancer Clin Pract. 2017;15:6.

9. Chhibber V, Dresser K, Mahalingam M. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod Pathol. 2008;21:159-164.